Atlas Copco AB Series B (ATCO-B)
Nasdaq Stockholm · Sweden · prices in SEK · close of 27 Oct 2026
Key indicators
| Last close | SEK 163.65 |
|---|---|
| 52-week range | 134.00 – 186.50 |
| Return, 1 month / 3 months | −8.0% / −8.0% |
| Return, 1 year / 3 years | +8.7% / +36.9% |
| Trend | Below its 200-day average |
| RSI (14) | 39 |
| Volatility (1 year) | 28.4% |
| Worst drawdown (1 year) | -17.5% |
| Average daily value traded | 269.62M SEK |
| Dividend yield | 2.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Atlas Copco is a Swedish industrial company that makes compressors, vacuum pumps and air treatment equipment for factories and other industrial customers. It also supplies power tools, assembly systems and related service support to manufacturers around the world. The business is based in Stockholm, Sweden, and serves customers in many industries through its own divisions and service network.
Atlas Copco AB Series B trades under the code ATCO-B on the Nasdaq Stockholm in Sweden, with its price quoted in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Atlas Copco AB Series B (ATCO-B) trades on the Nasdaq Stockholm in Sweden. It last closed at SEK 163.65 on 27 October 2026.
Its price-based Market X-Ray is 74 out of 100 (a strong price profile), ranking 134 of 912 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 8.7% and over the last three months it fell 8.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Nasdaq Stockholm
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 70 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | -1.5% | ||
| From 52-week high | -11.8% | ||
| Momentum | 61 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -8.0% | ||
| 6-month return | 1.3% | ||
| 12-month return, skipping the last month | 18.1% | ||
| Stability (higher is calmer) | 88 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 28.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -17.5% | ||
| Liquidity | 97 · Strong | Trades actively. | |
| Average daily value traded | 269.62M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | 48 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.1% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | −2.7% |
|---|---|
| 1 month | −8.0% |
| 3 months | −8.0% |
| 6 months | +1.3% |
| 1 year | +8.7% |
| 3 years | +36.9% |
| 5 years | +75.9% |
Signals
| 50-day / 200-day average | 175.58 / 166.06 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 4.77 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 19 Oct 2026 | SEK 2.5000 |
| 29 Apr 2026 | SEK 1.0000 |
| 20 Oct 2025 | SEK 1.5000 |
| 30 Apr 2025 | SEK 1.5000 |
| 18 Oct 2024 | SEK 1.4000 |
| 25 Apr 2024 | SEK 1.4000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Nasdaq Stockholm; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.